EU approves Xultophy for treatment of Type 2 Diabetes- Novo Nordisk
Novo Nordisk announced that the European Commission has granted marketing authorisation for Xultophy for the treatment of Type 2 Diabetes Mellitus in adults. The authorisation covers all 27 European Union member states. Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza).
Xultophy is indicated for the treatment of adults with Type 2 Diabetes Mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins